Inspiring Trust In Industry Practices

By Suresh Kumar

Current drug pricing is a mainstream issue that cannot be expediently blamed on fringe players or obfuscated by participants across the healthcare delivery chain, or by any of them blaming the others. The issue of price and affordability must be addressed by what is now perceived as a status-quo-happy healthcare industry.

Let’s look at the relentless focus on healthcare costs through the lens of Sovaldi (see box) which, at $1,000 per pill, galvanized voter sentiment across party lines, to underscore the growing divergence between industry practices and commercial principles.